MedTrace Logo

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

NCT00547534 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2015-08-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

bortezomib

1.3 mg/m\^2 on days 1, 4, 8, 11

DRUG

bendamustine

90 mg/m\^2 days 1 and 4

DRUG

rituximab

375 mg/m\^2 day 1

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Cephalon

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Principal Investigators

  • Jonathan Friedberg, md · University of Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-06-30
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547534 on ClinicalTrials.gov